News

Jeito Capital Elevates Ksenija Pavletic to General Partner Role

Jeito Capital Elevates Ksenija Pavletic to General Partner Role

Jeito Capital Announces Ksenija Pavletic's Promotion

In a significant move, Jeito Capital has proudly promoted Ksenija Pavletic to the role of General Partner. This promotion reinforces the firm's dedication to bolstering its leadership team as it actively expands its portfolio of innovative healthcare companies.

A Leader in Healthcare and Investment

Ksenija Pavletic brings over 25 years of comprehensive experience in healthcare and investment. Her blend of operational and strategic expertise is reflected through her various leadership roles within clinical-stage biopharmas across regional and global levels.

Contributions to Jeito Capital

Pavletic, a key member of Jeito’s founding team, has been instrumental in the firm’s success since its inception. Initially joining as an Operational Investor and Chief Commercial Officer, she has effectively utilized her distinctive business acumen to engage in critical functions within the pharmaceutical sector, alongside Jeito’s unique expertise across the drug development process.

Her promotion to Partner in 2024 was a natural progression given her exceptional contributions, which have aided in strengthening Jeito’s portfolio by merging commercial insight with operational support for numerous companies.

Impact on Therapeutic Investments

Ksenija has significantly influenced Jeito's investments in vital therapeutic areas, notably oncology, neuro-metabolic diseases, reproductive medicine, and women’s health. Recently, she has played a pivotal role in investments such as ReproNovo, which focuses on innovative treatments in reproductive health, and Odyssey Therapeutics, a biotechnology company committed to addressing autoimmune and inflammatory diseases.

Past Achievements and Future Directions

Before joining Jeito Capital, Pavletic was the CEO of PregLem SA, a notable Swiss reproductive health company. Under her leadership, the company experienced rapid growth and was sold for CHF 445 million within three years of its establishment. Earlier in her career, she held various senior commercial roles at Serono, which is now part of Merck Serono.

In her expanded role as General Partner, Pavletic aims to propel investments further, assisting portfolio companies in accelerating their clinical development while promoting international growth initiatives for Jeito.

Board Memberships and Influence

Currently, Pavletic holds positions on the boards of notable companies including Azafaros, Callio Therapeutics, Odyssey Therapeutics, and ReproNovo. Her insights and influence on these boards are pivotal in shaping the strategies of these dynamic firms.

Leadership Vision at Jeito Capital

Dr. Rafaèle Tordjman, the Founder and CEO of Jeito Capital, conveyed his enthusiasm regarding Pavletic's promotion by stating that it reflects her deep and impactful contributions to the firm as well as their collective commitment to building a world-class leadership team. He emphasized that her experience in the biopharma sector aligns with Jeito's vision to foster long-term positive outcomes for patients worldwide.

In reflecting on her advancement, Ksenija expressed gratitude for the trust placed in her by Dr. Tordjman, emphasizing her dedication to reinforcing Jeito’s mission of supporting transformative healthcare innovations. She views this opportunity as a chance to make a deeper impact and aid in cultivating the next generation of groundbreaking biopharma companies.

About Jeito Capital

Jeito Capital is recognized as a leading global private equity fund focused on biopharma, applying a patient-centric approach to finance and expedite the development of revolutionary medical innovations. The firm leverages its substantial capital, alongside a skilled, multifaceted team, to foster and support growth among its portfolio companies, aspiring to create market leaders in critical therapeutic domains.

With a commitment to addressing significant unmet medical needs, Jeito Capital has cultivated a diverse portfolio of innovative biopharma entities. The firm maintains a presence in global markets, particularly across Europe and the United States, and is dedicated to improving patients' access to essential treatments.

Frequently Asked Questions

Who is Ksenija Pavletic?

Ksenija Pavletic is a seasoned healthcare and investment leader with over 25 years of experience. She recently became General Partner at Jeito Capital.

What role did Ksenija play in Jeito Capital?

Ksenija has been a vital part of Jeito since its inception, contributing to portfolio growth through her operational and commercial expertise.

What are some areas Jeito Capital invests in?

Jeito Capital focuses on high-potential therapeutic areas such as oncology, reproductive medicine, and autoimmune diseases.

What did Ksenija achieve before joining Jeito Capital?

Prior to Jeito, Ksenija was CEO of PregLem SA, where she led significant growth and the company's successful sale.

How is Jeito Capital structured?

Jeito Capital is a private equity fund dedicated to biopharma, with a team that integrates medical and commercial insights to drive company success.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 147

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Early Dog Guarding Signs Matter Before a Sudden Growl

Updated Category News Views 92

A bowl, a chewed-up toy, or a patch of couch can turn tense in a heartbeat. That is why the useful part of Brian Manning's guidance is not some fantasy of making every dog endlessly tolerant; it is learning to notice discomfort while there is still room to back off safely. For anybody watching the pet-care and behavior-training field, this is the kind of plainspoken...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 245

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 115

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 168

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 158

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 54

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 68

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 124

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading

Top 5 Most Recently Viewed Articles

Hepsiburada's Impressive Q3 2025 Performance Review

Updated Category News Views 281

Hepsiburada Reports Significant Gains in Q3 2025 Hepsiburada, officially known as D-MARKET Electronic Services & Trading (NASDAQ: HEPS), has unveiled robust financial results for the third quarter of 2025. The Turkish e-commerce giant reported an impressive increase in gross merchandise value (GMV) and revenue, highlighting the company's operational resilience in a...

Continue Reading
Fulcrum Therapeutics Faces Challenges Amid Sickle Cell Trials

Updated Category News Views 212

Market Moves and Stock Reactions So, let’s get straight to the meat of it. Fulcrum Therapeutics Inc. (NASDAQ:FULC) took a nosedive recently—down about 10%—right after they dropped the latest news on their Phase 1b trial for pociredir aimed at treating sickle cell disease. Stock fell to around $9.80, and honestly, if you're still holding shares, well, it's time to...

Continue Reading
SBM Offshore's Share Repurchase Program Insights and Updates

Updated Category News Views 215

Overview of SBM Offshore’s Share Repurchase Program SBM Offshore has recently conducted a significant share repurchase program amounting to EUR141 million (approximately US$150 million). This initiative began on April 24, 2025, and aims to reduce share capital while also supporting management and employee share programs. The program has been designed to both enhance...

Continue Reading
Plymouth Industrial REIT Responds to Acquisition Proposal

Updated Category News Views 212

Plymouth Industrial REIT Receives Unsolicited Acquisition Proposal Plymouth Industrial REIT, Inc. (NYSE: PLYM), a leader in the industrial real estate sector, recently attracted attention with an unsolicited and non-binding acquisition proposal. This proposal comes from Sixth Street Partners, LLC, and suggests a price of $24.10 per share for all outstanding shares of the...

Continue Reading
Middlefield Canadian Income PCC AGM Results Breakdown

Updated Category News Views 230

Overview of the AGM Results for Middlefield Canadian Income PCC Middlefield Canadian Income PCC (the "Company") and Middlefield Canadian Income - GBP PC (the "Cell") have recently concluded their annual general meeting, a significant event that spotlighted the Company's journey and future direction. Conducted with transparency and diligence, this meeting has underscored...

Continue Reading